Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||TP53 mutant|
|Therapy||Obinutuzumab + Venetoclax|
|Indication/Tumor Type||chronic lymphocytic leukemia|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 mutant||chronic lymphocytic leukemia||sensitive||Obinutuzumab + Venetoclax||Guideline||Actionable||Venclexta (venetoclax) and Gazyva (obinutuzumab) combination therapy is included in the guidelines as first-line therapy for patients with advanced chronic lymphocytic leukemia harboring TP53 mutations and for patients with relapsed or refractory disease (PMID: 33091559; ESMO.org).||33091559 detail...|
|PubMed Id||Reference Title||Details|
|ESMO Clinical Practice Guidelines||Full reference...|
|(33091559)||Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.||Full reference...|